Pembrolizumab and atezolizumab USPIs updated by FDA – Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR

Non-Sponsored Content

PD-L1 test required for immunotherapy in cisplatin-ineligible urothelial carcinoma patients

By: News Feed | Last updated: 21st August 2018 | In: Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals

Article Keywords

22C3, atezolizumab, CDx, cisplatin, CPS, DAKO, FDA, Genentech, Keytruda, Merck, MSD, PD-L1, pembrolizumab, Roche, SP142, Tecentriq, urothelial carcinoma, Ventana

On the 16th of August 2018, the FDA updated the prescribing information for pembrolizumab (Keytruda®, Merck) and atezolizumab (Tecentriq®, Roche/Genentech) and added the requirement for the use of an FDA-approved companion diagnostic test (CDx) to determine PD-L1 level expression in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Pembrolizumab CDx

The FDA cleared the Dako PD-L1 IHC 22C3 PharmDx Assay® (Dako North America) to determine the combined positive score (CPS) by assessing the PD-L1 level expression in both tumour and immune cells for selection of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma for pembrolizumab treatment./

Pembrolizumab is now indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy and a CPS ≥ 10, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 level expression.

Keytruda® Prescribing Information

Atezolizumab CDx

The FDA cleared the Ventana PD-L1 (SP142) Assay® (Ventana Medical Systems) to determine PD L1 expression in immune cells for selection of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma for atezolizumab treatment.

Atezolizumab is now indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy, and with PD-L1 stained tumour-infiltrating immune cells covering ≥5% of the tumour area, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 level expression.

Tecentriq® Prescribing Information

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

Trackbacks & Pingbacks

Approved Immune-Checkpoint Inhibitors and Immunotherapies says:

20th November 2018 at 10:22 AM

[…] Ineligible for cisplatin-based chemotherapy and a CPS (combined positive score: PD-L1 level expression on tumour and immune cells)≥10, or; […]

Log in to Reply

Want to join the discussion?
Feel free to contribute!